ReviewFrontiers in cardiovascular medicine2026
The gut microbiota-aromatic amino acid axis in cardiovascular disease: pathophysiological roles, translational biomarkers, and therapeutic targeting.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) remains a leading global health burden, with conventional risk factors lacking sufficient predictive power. Gut microbiota-derived aromatic amino acid (AAA) metabolites and oxidative tyrosine post-translational modifications (PTMs) have emerged as novel pathophysiological regulators of CVD, but their integrated mechanistic roles, clinical biomarker value, and therapeutic potential remain to be systematically elucidated. Methods: A review on gut microbiota-AAA axis in CVD was conducted, synthesizing mechanistic, clinical, and translational evidence of AAA metabolites (phenylalanine, tryptophan, tyrosine derivatives) and tyrosine PTMs in the pathogenesis of CVD. We also analyzed the diagnostic potential of multi-omics identified combinatorial biomarkers and the preclinical/clinical evidence for targeted therapeutic strategies. Results: Phenylacetylglutamine (PAGln) activates Conclusions: The gut microbiota-AAA axis integrates dysbiosis, inflammation, and oxidative stress to drive CVD pathogenesis, with its metabolites and PTMs providing complementary diagnostic value. If validated, interventions targeting this axis may improve CVD risk assessment and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.